Search Results - "Barreto, Joaquim"

Intersoftware variability impacts classification of cardiac PET exams by Oliveira, Joaquim Barreto, Sen, Yew Min, Wechalekar, Kshama

“…Myocardial perfusion imaging (MPI) with 82Rb PET/CT is increasingly utilized in the evaluation of coronary artery disease with high diagnostic accuracy…”
Get full text

Effect of aluminum accumulation on bone and cardiovascular risk in the current era by Carbonara, Cinthia E M, Roza, Noemi A V, Quadros, Kelcia R S, França, Renata A, Esteves, André B A, Pavan, Celia R, Barreto, Joaquim, Dos Reis, Luciane M, Jorgetti, Vanda, Sposito, Andrei C, Oliveira, Rodrigo Bueno

“…The prevalence of aluminum (Al) intoxication has declined over the past 3 decades. However, different groups still report on the diagnosis of Al in bone…”
Get full text

High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction by Carmo, Helison R P, Bonilha, Isabella, Barreto, Joaquim, Tognolini, Massimiliano, Zanotti, Ilaria, Sposito, Andrei C

“…Despite significant therapeutic advancements, morbidity and mortality following myocardial infarction (MI) remain unacceptably high. This clinical challenge is…”
Get full text

Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction by Sposito, Andrei C., de Lima-Junior, José Carlos, Moura, Filipe A., Barreto, Joaquim, Bonilha, Isabella, Santana, Michele, Virginio, Vitor W., Sun, Lufan, Carvalho, Luiz Sergio F., Soares, Alexandre A.S., Nadruz, Wilson, Feinstein, Steve B., Nofer, Jerzy-Roch, Zanotti, Ilaria, Kontush, Anatol, Remaley, Alan T.

“…Despite decades of therapeutic advances, myocardial infarction remains a leading cause of death worldwide. Recent studies have identified HDLs (high-density…”
Get full text

Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial by Sposito, Andrei C, Breder, Ikaro, Soares, Alexandre A S, Kimura-Medorima, Sheila T, Munhoz, Daniel B, Cintra, Riobaldo M R, Bonilha, Isabella, Oliveira, Daniela C, Breder, Jessica Cunha, Cavalcante, Pamela, Moreira, Camila, Moura, Filipe A, de Lima-Junior, Jose Carlos, do Carmo, Helison R P, Barreto, Joaquim, Nadruz, Wilson, Carvalho, Luiz Sergio F, Quinaglia, Thiago

“…The glucose-lowering independent effect of sodium glucose cotransporter-2 inhibitors (SGLT2i) on arterial wall function has not yet been clarified. This study…”
Get full text

Diabetes-related distress and quality of life among people with type 2 diabetes at primary care level in Brazil by Neves, Natália Wilcesky Tosini, Breder, Jéssica Silva Cunha, Oliveira, Bruna Andrade, Zanchetta, Flávia Cristina, Barreto, Joaquim, Sposito, Andrei C., Lima, Maria Helena Melo

“…Purpose Living with diabetes can be challenging, particularly when it comes to dealing with psychological distress and requiring self-care directives. Patients…”
Get full text

Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial by Bonilha, Isabella, Gomes, Érica Ivana Lázaro, Carmo, Helison R P, Breder, Ikaro, Barreto, Joaquim, Breder, Jessica, Munhoz, Daniel B, Carvalho, Luiz Sergio F, Quinaglia, Thiago, Kimura-Medorima, Sheila T, Gossi, Camila Moreira, Zimetti, Francesca, Nadruz, Wilson, Zanotti, Ilaria, Sposito, Andrei C

“…Evolocumab and empagliflozin yield a modest rise in plasma high-density lipoprotein cholesterol (HDL-C) through unknown mechanisms. This study aims to assess…”
Get full text

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial by Sposito, Andrei C, Breder, Ikaro, Barreto, Joaquim, Breder, Jessica, Bonilha, Isabella, Lima, Marcus, Oliveira, Alessandra, Wolf, Vaneza, Luchiari, Beatriz, do Carmo, Helison R, Munhoz, Daniel, Oliveira, Daniela, Coelho-Filho, Otavio R, Coelho, Otavio R, Matos-Souza, Jose Roberto, Moura, Filipe A, de Carvalho, Luiz Sergio F, Nadruz, Wilson, Quinaglia, Thiago, Kimura-Medorima, Sheila T

“…Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D)…”
Get full text

Skin accumulation of advanced glycation end-products predicts kidney outcomes in type 2 diabetes: results from the Brazilian Diabetes Study by Barreto, Joaquim, Martins, Marilia, Borges, Cynthia M, Vitte, Sofia Helena, Nadruz Junior, Wilson, Oliveira, Rodrigo Bueno de, Sposito, Andrei C

“…The accumulation of advanced glycation end-products (AGEs) elicits morphofunctional kidney impairment. AGEs levels can be noninvasively estimated by skin…”
Get full text

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus by Wolf, Vaneza Lira W., Breder, Ikaro, de Carvalho, Luiz Sérgio F., Soares, Alexandre A. S., Cintra, Riobaldo M., Barreto, Joaquim, Munhoz, Daniel B., Kimura-Medorima, Sheila T., Nadruz, Wilson, Guerra-Júnior, Gil, Quinaglia, Thiago, Muscelli, Elza, Sposito, Andrei C.

“…We compared the effect of dapagliflozin versus glibenclamide on the ratio of lean-to total mass in patients with type 2 diabetes mellitus, carotid subclinical…”
Get full text

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives by Barreto, Joaquim, Campos-Staffico, Alessandra M, Nadruz, Wilson, Quinaglia, Thiago, Sposito, Andrei C

“…Sodium glucose cotransporter 2 inhibitors (SGLT2) have been increasingly pursued as a promising target for addressing residual cardiovascular risk. Prior…”
Get full text

Renal osteodystrophy and clinical outcomes: a prospective cohort study by Carbonara, Cinthia Esbrile Moraes, Barreto, Joaquim, Roza, Noemi Angelica Vieira, Quadros, KélciaRosana da Silva, Reis, Luciene Machado Dos, Carvalho, Aluízio Barbosa de, Sposito, Andrei C, Jorgetti, Vanda, Oliveira, Rodrigo Bueno de

“…Renal osteodystrophy (ROD) refers to a group of bone morphological patterns that derive from distinct pathophysiological mechanisms. Whether the ROD subtypes…”
Get full text

Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model by Nogueira, Ana Claudia Cavalcante, Barreto, Joaquim, Moura, Filipe A., Luchiari, Beatriz, Abuhab, Abrão, Bonilha, Isabella, Nadruz, Wilson, Gaziano, J. Michael, Gaziano, Thomas, de Carvalho, Luiz Sergio F., Sposito, Andrei C.

“…Background The escalating prevalence of type 2 diabetes (T2DM) poses an unparalleled economic catastrophe to developing countries. Cardiovascular diseases…”
Get full text

Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis by de Carvalho, Luiz Sergio Fernandes, Nogueira, Ana Claudia Cavalcante, Bonilha, Isabella, Luchiari, Beatriz, Benchimol, Alexander, Couri, Carlos Eduardo Barra, Borges, Jairo Lins, Barreto, Joaquim, Sposito, Andrei C

“…To assess the impact of the HbA1c levels achieved with antidiabetic therapies (ADTs) on the risk of MACE. A systematic search was performed in PubMed,…”
Get full text

Aspirin in primary prevention and the risk of heart failure: a systematic review and meta‐analysis of controlled trials by Oliveira, Ana Beatrice Magalhães, Luchiari, Beatriz, Bonilha, Isabella, Barreto, Joaquim, Nogueira, Ana Claudia Cavalcante, Ceniccola, Guilherme Duprat, Polanczyk, Carisi Anne, Sposito, Andrei Carvalho, Carvalho, Luiz Sérgio Fernandes

“…At first, in this observational study it is not possible to avoid potential selection biases, that is, physicians tend to prescribe drugs believed to be…”
Get full text

Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease by Quadros, Kélcia R. S., Roza, Noemi A. V., França, Renata A., Esteves, André B. A., Barreto, Joaquim, Dominguez, Wagner V., Furukawa, Luzia N. S., Caramori, Jacqueline Teixeira, Sposito, Andrei C., Oliveira, Rodrigo Bueno

“…ABSTRACT Advanced glycation end products (AGEs) accumulation may be involved in the progression of CKD‐bone disorders. We sought to determine the relationship…”
Get full text

Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis by Barreto, Joaquim, Luchiari, Beatriz, Wolf, Vaneza L W, Bonilha, Isabella, Bovi, Ticiane G, Assato, Barbara S, Breder, Ikaro, Kimura-Medorima, Sheila T, Munhoz, Daniel B, Quinaglia, Thiago, Coelho-Filho, Otavio R, Carvalho, Luiz Sergio F, Nadruz, Wilson, Sposito, Andrei C

“…Stricter control of risk factors has been pursued as a compelling strategy to mitigate cardiovascular events (CVE) in type 2 diabetes (T2D) individuals…”
Get full text

O Impacto da Educação na Mortalidade por Todas as Causas após Infarto do Miocárdio com Supradesnivelamento do Segmento ST (IAMCSST): Resultados do Brasília Heart Study by Barreto, Joaquim, Silva, Jose Carlos Quinaglia e, Sposito, Andrei C., Carvalho, Luiz Sergio

“…Resumo Fundamento A baixa escolaridade tem sido considerada um fator de risco modificável significativo para o desenvolvimento de doenças cardiovasculares há…”
Get full text

Associação Positiva entre Autoanticorpos contra LDL Oxidada e HDL-C: Um Novo Mecanismo para Cardioproteção de HDL? by Nunez, Carla Evelyn Coimbra, Oliveira, Joaquim Barreto, Barros-Mazon, Silvia de, Zago, Vanessa H. S., Kaplan, Denise Beheregaray, Nakamura, Ruy T., Gidlund, Magnus Ake, Gomes, Erica I. L., Cazita, Patricia Miralda, Nakandakare, Edna, Carmo, Helison R., Sposito, Andrei C., Faria, Eliana Cotta de

“…Resumo Fundamento No microambiente da placa aterosclerótica, os fosfolipídios oxidados expressos na superfície de lipoproteína de baixa densidade oxidada…”
Get full text

Role of LOX-1 (Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1) as a Cardiovascular Risk Predictor: Mechanistic Insight and Potential Clinical Use by Barreto, Joaquim, Karathanasis, Sotirios K., Remaley, Alan, Sposito, Andrei C.

“…Atherosclerosis, the underlying cause of cardiovascular disease (CVD), is a worldwide cause of morbidity and mortality. Reducing ApoB-containing…”
Get full text